MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
MEI Pharma ROE Ratio 2011-2026 | MEIP
Annual ROE Ratio MEI Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -94.18 | 53.84 | -129.3 | -103.89 | -83.52 | -61.22 | -35.09 | -79.41 | 5.25 | -50.09 | -54.68 | -60.07 | -32.08 | -163.58 | -377.98 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.84 | -377.98 | -84.4 |
Quarterly ROE Ratio MEI Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -67.2 | -41.69 | -57.47 | -75.35 | -80.07 | -86.55 | 32.81 | -12.13 | -39.18 | 0.61 | -68.3 | -80.46 | -48.39 | -86.16 | -92.65 | -140.46 | -178.64 | -172.28 | -136.82 | -92.43 | -43.92 | -59.87 | -70.44 | -81.02 | -84.81 | -36.16 | 12.49 | 61.13 | 30.89 | -7.45 | -50.11 | -88.44 | -72.04 | -34.54 | -24.45 | 19.93 | 29.85 | -1.68 | 0.15 | -36.92 | -34.4 | -37.02 | -52.67 | -64.3 | -76.47 | -74.74 | -66.54 | -55.6 | -43.6 | -43.51 | -118.22 | -168.88 | -214.56 | -243.13 | -200.76 | -226.77 | -263.05 | -48.05 | -85.9 | -89.86 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.13 | -263.05 | -71.14 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
-48.89 | $ 3.02 | 1.0 % | $ 258 M |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
1.11 | $ 90.9 | -0.31 % | $ 27.2 B | Germany |
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Codexis
CDXS
|
-87.03 | $ 1.93 | 6.04 % | $ 168 M | USA |
 |
Cerus Corporation
CERS
|
-24.33 | $ 1.9 | 1.88 % | $ 362 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Cullinan Management
CGEM
|
-53.8 | $ 15.2 | 5.34 % | $ 916 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.69 | -2.31 % | $ 198 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-123.35 | $ 0.46 | -13.46 % | $ 5.27 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-350.48 | $ 2.27 | 0.39 % | $ 1.01 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
22.46 | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 8.3 | 3.36 % | $ 227 M | Israel |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 10.37 | 1.97 % | $ 138 M | USA |
 |
Cardiff Oncology
CRDF
|
-101.02 | $ 1.6 | 0.95 % | $ 107 M | USA |
 |
Curis
CRIS
|
-138.81 | $ 0.53 | -3.64 % | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 38.09 | 2.31 % | $ 3.58 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 49.43 | -0.17 % | $ 4.44 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 4.41 | -3.4 % | $ 608 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-56.26 | $ 0.87 | 1.26 % | $ 5.85 M | USA |
 |
Cue Biopharma
CUE
|
-100.64 | $ 0.17 | -7.12 % | $ 16.1 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 31.43 | 1.18 % | $ 2.09 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
-34.54 | $ 4.34 | -29.51 % | $ 10.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |